NAS:GRFS (Spain) Also trade in: Austria Germany Mexico Spain UK

Grifols SA

$ 20.12 0.08 (0.4%)
Volume: 1,046,075 Avg Vol (1m): 977,208
Market Cap $: 17.26 Bil Enterprise Value $: 17.32 Bil
P/E (TTM): 30.30 P/B: 3.87
Earnings Power Value 9.56
Net Current Asset Value -6.5
Tangible Book -3.57
Projected FCF 9.46
Median P/S Value 19.95
Graham Number 0
Peter Lynch Value 4.36
DCF (FCF Based) 1.81
DCF (Earnings Based) 14.51
1Y (-%)

Financial Strength : 6/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 2.29
Cash-To-Debt ranked lower than
100.00% of 859 companies
in the Drug Manufacturers - Major industry.
Industry Max: 91151, Med: 2.03, Min: -0.01
GRFS: 2.29
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.03, Med: 0.18, Max: 10000
Current: 2.29
0.03
10000
Equity-to-Asset 0.33
Equity-to-Asset ranked lower than
79.06% of 788 companies
in the Drug Manufacturers - Major industry.
Industry Max: 1.78, Med: 0.64, Min: -27.83
GRFS: 0.33
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.28, Med: 0.33, Max: 0.37
Current: 0.33
0.28
0.37
Debt-to-Equity 0.08
Debt-to-Equity ranked lower than
75.34% of 596 companies
in the Drug Manufacturers - Major industry.
Industry Max: 31.22, Med: 0.32, Min: 0.01
GRFS: 0.08
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: 0.04, Med: 1.45, Max: 5.26
Current: 0.08
0.04
5.26
Debt-to-EBITDA 0.27
Debt-to-EBITDA ranked higher than
66.67% of 495 companies
in the Drug Manufacturers - Major industry.
Industry Max: 343059.67, Med: 1.92, Min: 0.01
GRFS: 0.27
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: 0.27, Med: 4.29, Max: 8.67
Current: 0.27
0.27
8.67
Interest Coverage 3.28
Interest Coverage ranked lower than
71.14% of 648 companies
in the Drug Manufacturers - Major industry.
Industry Max: 2689668, Med: 86.08, Min: 0.01
GRFS: 3.28
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 1.63, Med: 4.07, Max: 18.16
Current: 3.28
1.63
18.16
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 1.87
DISTRESS
GREY
SAFE
Beneish M-Score -1.99
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 13.24%
WACC 3.39%

Profitability & Growth : 7/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 21.22
Operating Margin ranked higher than
90.26% of 801 companies
in the Drug Manufacturers - Major industry.
Industry Max: 8950, Med: 7.97, Min: -232970.37
GRFS: 21.22
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: 15.53, Med: 23.94, Max: 26.85
Current: 21.22
15.53
26.85
Net Margin % 12.28
Net Margin ranked higher than
86.03% of 802 companies
in the Drug Manufacturers - Major industry.
Industry Max: 304900, Med: 5.32, Min: -216285.19
GRFS: 12.28
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: 2.8, Med: 13.39, Max: 16.2
Current: 12.28
2.8
16.2
ROE % 13.88
ROE ranked higher than
86.18% of 832 companies
in the Drug Manufacturers - Major industry.
Industry Max: 316.96, Med: 5.94, Min: -3119.47
GRFS: 13.88
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: 4.27, Med: 17.62, Max: 28.28
Current: 13.88
4.27
28.28
ROA % 4.73
ROA ranked higher than
80.83% of 871 companies
in the Drug Manufacturers - Major industry.
Industry Max: 943.36, Med: 2.88, Min: -1851.14
GRFS: 4.73
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: 1.34, Med: 5.97, Max: 10.43
Current: 4.73
1.34
10.43
ROC (Joel Greenblatt) % 30.02
ROC (Joel Greenblatt) ranked higher than
85.85% of 855 companies
in the Drug Manufacturers - Major industry.
Industry Max: 34233.33, Med: 11.23, Min: -2671900
GRFS: 30.02
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: 18.09, Med: 32.72, Max: 42.62
Current: 30.02
18.09
42.62
3-Year Total Revenue Growth Rate 4.50
3-Year Revenue Growth Rate ranked higher than
64.73% of 689 companies
in the Drug Manufacturers - Major industry.
Industry Max: 291.9, Med: 5.8, Min: -100
GRFS: 4.4
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -5.6, Med: 10.4, Max: 51.6
Current: 4.4
-5.6
51.6
3-Year Total EBITDA Growth Rate 3.60
3-Year EBITDA Growth Rate ranked lower than
54.55% of 704 companies
in the Drug Manufacturers - Major industry.
Industry Max: 299.6, Med: 7.3, Min: -343.2
GRFS: 3.6
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: 3.6, Med: 12.5, Max: 39
Current: 3.6
3.6
39
3-Year EPS w/o NRI Growth Rate 3.70
3-Year EPS w/o NRI Growth Rate ranked higher than
51.28% of 663 companies
in the Drug Manufacturers - Major industry.
Industry Max: 385.8, Med: 8.9, Min: -403.2
GRFS: 3.7
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: -13.8, Med: 16.2, Max: 62.8
Current: 3.7
-13.8
62.8

» GRFS's 30-Y Financials

Financials (Next Earnings Date: 2019-07-26)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:GRFS

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Major    NAICS : 325412    SIC : 0
Compare TSE:4578 HKSE:01093 TSE:4151 SHSE:600436 TSE:4528 MIL:REC TSE:4503 BOM:500302 BOM:500087 SZSE:002422 TSE:4536 TSE:2784 TSE:9987 OTCPK:GWPRF ISX:KLBF SZSE:300146 SHSE:600867 SZSE:002399 NSE:TORNTPHARM XKRX:008930
Traded in other countries GRF.Austria G0FB.Germany GRFPN.Mexico GRF.P.Spain 0RDU.UK
Address Avinguda de la Generalitat, 152-158, Parque empresarial Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's bioscience business contributed 79% of sales in 2017. Grifols also has smaller segments including diagnostics, hospital supplies, and biosupplies. Diagnostics grew to almost 20% of revenue in 2014 with the acquisition of Novartis' diagnostics unit.

Ratios

Current vs industry vs history
PE Ratio (TTM) 30.30
PE Ratio ranked higher than
74.15% of 557 companies
in the Drug Manufacturers - Major industry.
Industry Max: 1910, Med: 23.77, Min: 0.06
GRFS: 30.3
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 21.73, Med: 29.38, Max: 81.6
Current: 30.3
21.73
81.6
Forward PE Ratio 17.36
Forward P/E ranked higher than
68.47% of 111 companies
in the Drug Manufacturers - Major industry.
Industry Max: 322.58, Med: 21.6, Min: 5.03
GRFS: 17.36
Ranked among companies with meaningful Forward P/E only.
N/A
PE Ratio without NRI 30.30
PE without NRI ranked higher than
74.64% of 556 companies
in the Drug Manufacturers - Major industry.
Industry Max: 2125, Med: 24.2, Min: 0.06
GRFS: 30.3
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 21.73, Med: 29.38, Max: 81.6
Current: 30.3
21.73
81.6
Price-to-Owner-Earnings 98.59
Price-to-Owner-Earnings ranked lower than
100.00% of 324 companies
in the Drug Manufacturers - Major industry.
Industry Max: 3160, Med: 31.95, Min: 0.17
GRFS: 98.59
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 18.11, Med: 34.15, Max: 100.16
Current: 98.59
18.11
100.16
PB Ratio 3.87
PB Ratio ranked lower than
60.32% of 819 companies
in the Drug Manufacturers - Major industry.
Industry Max: 227.39, Med: 2.64, Min: 0.05
GRFS: 3.87
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 2.32, Med: 4.25, Max: 6.76
Current: 3.87
2.32
6.76
PS Ratio 3.69
PS Ratio ranked higher than
61.81% of 775 companies
in the Drug Manufacturers - Major industry.
Industry Max: 9105.26, Med: 3.1, Min: 0.03
GRFS: 3.69
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 1.95, Med: 3.66, Max: 12.85
Current: 3.69
1.95
12.85
Price-to-Free-Cash-Flow 119.44
Price-to-Free-Cash-Flow ranked higher than
57.38% of 298 companies
in the Drug Manufacturers - Major industry.
Industry Max: 3143.75, Med: 30.84, Min: 0.23
GRFS: 119.44
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 15.6, Med: 35.3, Max: 121.38
Current: 119.44
15.6
121.38
Price-to-Operating-Cash-Flow 36.11
Price-to-Operating-Cash-Flow ranked higher than
58.16% of 392 companies
in the Drug Manufacturers - Major industry.
Industry Max: 14229.87, Med: 22, Min: 0.23
GRFS: 36.11
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 11.02, Med: 20.25, Max: 169.33
Current: 36.11
11.02
169.33
EV-to-EBIT 15.31
EV-to-EBIT ranked higher than
73.25% of 572 companies
in the Drug Manufacturers - Major industry.
Industry Max: 1015380.11, Med: 17.85, Min: 0.13
GRFS: 15.31
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: 14.1, Med: 19.5, Max: 45.1
Current: 15.31
14.1
45.1
EV-to-EBITDA 12.25
EV-to-EBITDA ranked higher than
74.37% of 597 companies
in the Drug Manufacturers - Major industry.
Industry Max: 341528.02, Med: 15.24, Min: 0.12
GRFS: 12.25
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: 11.7, Med: 16, Max: 37.1
Current: 12.25
11.7
37.1
EV-to-Revenue 3.27
EV-to-Revenue ranked higher than
68.93% of 795 companies
in the Drug Manufacturers - Major industry.
Industry Max: 23858.8, Med: 3.24, Min: 0.03
GRFS: 3.27
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 3.3, Med: 4.5, Max: 12.8
Current: 3.27
3.3
12.8
PEG Ratio 4.23
PEG Ratio ranked higher than
72.87% of 317 companies
in the Drug Manufacturers - Major industry.
Industry Max: 1472, Med: 1.93, Min: 0.07
GRFS: 4.23
Ranked among companies with meaningful PEG Ratio only.
PEG Ratio range over the past 10 years
Min: 0.54, Med: 2.39, Max: 4.68
Current: 4.23
0.54
4.68
Current Ratio 2.87
Current Ratio ranked lower than
81.29% of 855 companies
in the Drug Manufacturers - Major industry.
Industry Max: 413.44, Med: 2.39, Min: 0.02
GRFS: 2.87
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 1.57, Med: 2.96, Max: 3.36
Current: 2.87
1.57
3.36
Quick Ratio 1.13
Quick Ratio ranked lower than
100.00% of 855 companies
in the Drug Manufacturers - Major industry.
Industry Max: 413.44, Med: 1.87, Min: 0.02
GRFS: 1.13
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.71, Med: 1.4, Max: 1.88
Current: 1.13
0.71
1.88
Days Inventory 271.34
Days Inventory ranked lower than
56.42% of 755 companies
in the Drug Manufacturers - Major industry.
Industry Max: 950.68, Med: 119.8, Min: 0.2
GRFS: 271.34
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 235.92, Med: 271.95, Max: 909.7
Current: 271.34
235.92
909.7
Days Sales Outstanding 47.14
Days Sales Outstanding ranked higher than
79.09% of 770 companies
in the Drug Manufacturers - Major industry.
Industry Max: 864.61, Med: 81.76, Min: 0.1
GRFS: 47.14
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 23.54, Med: 53.12, Max: 83.07
Current: 47.14
23.54
83.07
Days Payable 81.01
Days Payable ranked higher than
71.90% of 758 companies
in the Drug Manufacturers - Major industry.
Industry Max: 952.38, Med: 76.32, Min: 0.04
GRFS: 81.01
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 64.56, Med: 81.44, Max: 256.52
Current: 81.01
64.56
256.52

Dividend & Buy Back

Current vs industry vs history
Dividend Yield % 2.02
Trailing Dividend Yield ranked higher than
93.09% of 752 companies
in the Drug Manufacturers - Major industry.
Industry Max: 25.84, Med: 1.54, Min: 0.04
GRFS: 2.02
Ranked among companies with meaningful Trailing Dividend Yield only.
Trailing Dividend Yield range over the past 10 years
Min: 0.48, Med: 1.36, Max: 2.04
Current: 2.02
0.48
2.04
Dividend Payout Ratio 0.50
Dividend Payout Ratio ranked higher than
94.13% of 477 companies
in the Drug Manufacturers - Major industry.
Industry Max: 68, Med: 0.3, Min: 0.02
GRFS: 0.5
Ranked among companies with meaningful Dividend Payout Ratio only.
Dividend Payout Ratio range over the past 10 years
Min: 0.14, Med: 0.36, Max: 0.63
Current: 0.5
0.14
0.63
3-Year Dividend Growth Rate (Per Share) 7.70
3-Year Dividend Growth Rate ranked higher than
87.63% of 299 companies
in the Drug Manufacturers - Major industry.
Industry Max: 114, Med: 7.4, Min: -100
GRFS: 7.7
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
3-Year Dividend Growth Rate range over the past 10 years
Min: 0, Med: -100, Max: 46.3
Current: 7.7
0
46.3
Forward Dividend Yield % 1.75
Forward Dividend Yield ranked higher than
93.18% of 719 companies
in the Drug Manufacturers - Major industry.
Industry Max: 25.84, Med: 1.66, Min: 0.04
GRFS: 1.75
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield-on-Cost (5-Year) % 6.29
Yield-on-Cost (5y) ranked higher than
90.20% of 745 companies
in the Drug Manufacturers - Major industry.
Industry Max: 42.46, Med: 2.12, Min: 0.03
GRFS: 6.29
Ranked among companies with meaningful Yield-on-Cost (5y) only.
Yield-on-Cost (5y) range over the past 10 years
Min: 1.49, Med: 4.23, Max: 6.35
Current: 6.29
1.49
6.35
3-Year Share Buyback Rate -0.10
3-Year Share Buyback Rate ranked lower than
100.00% of 571 companies
in the Drug Manufacturers - Major industry.
Industry Max: 100, Med: -5.3, Min: -815
GRFS: -0.1
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -46.1, Med: -1.5, Max: 20.3
Current: -0.1
-46.1
20.3

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 2.13
Price-to-Intrinsic-Value-Projected-FCF ranked higher than
78.61% of 374 companies
in the Drug Manufacturers - Major industry.
Industry Max: 209, Med: 2.11, Min: 0.05
GRFS: 2.13
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 1.65, Med: 2, Max: 5.96
Current: 2.13
1.65
5.96
Price-to-DCF (Earnings Based) 1.39
Price-to-Intrinsic-Value-DCF (Earnings Based) ranked higher than
89.09% of 110 companies
in the Drug Manufacturers - Major industry.
Industry Max: 27.76, Med: 1.36, Min: 0.14
GRFS: 1.39
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.01
Price-to-Median-PS-Value ranked lower than
75.37% of 743 companies
in the Drug Manufacturers - Major industry.
Industry Max: 238.36, Med: 0.94, Min: 0.01
GRFS: 1.01
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.57, Med: 1.01, Max: 3.17
Current: 1.01
0.57
3.17
Price-to-Peter-Lynch-Fair-Value 4.61
Price-to-Peter-Lynch-Fair-Value ranked lower than
100.00% of 212 companies
in the Drug Manufacturers - Major industry.
Industry Max: 26.42, Med: 1.41, Min: 0.08
GRFS: 4.61
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
Price-to-Peter-Lynch-Fair-Value range over the past 10 years
Min: 0.95, Med: 2.45, Max: 4.63
Current: 4.61
0.95
4.63
Earnings Yield (Joel Greenblatt) % 6.52
Earnings Yield (Greenblatt) ranked higher than
82.47% of 867 companies
in the Drug Manufacturers - Major industry.
Industry Max: 769.23, Med: 3.31, Min: -333.33
GRFS: 6.52
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: 2.2, Med: 5.1, Max: 7.1
Current: 6.52
2.2
7.1
Forward Rate of Return (Yacktman) % 8.57
Forward Rate of Return ranked higher than
78.38% of 421 companies
in the Drug Manufacturers - Major industry.
Industry Max: 559.55, Med: 8.96, Min: -1635.32
GRFS: 8.57
Ranked among companies with meaningful Forward Rate of Return only.
Forward Rate of Return range over the past 10 years
Min: 8.5, Med: 14.5, Max: 23
Current: 8.57
8.5
23

More Statistics

Revenue (TTM) (Mil) $ 5,314.55
EPS (TTM) $ 0.95
Beta 0.95
Volatility % 14.9
52-Week Range $ 17.42 - 22.81
Shares Outstanding (Mil) 684.14

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA Y
Positive CFROA Y
Higher ROA yoy N
CFROA > ROA N
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y